Med. Klinik und Poliklinik II, Herzzentrum, Universitätsklinikum Bonn, Germany.
Cardiovascular Radiology, Faculty of Health Sciences, Rigshospitalet, Copenhagen, Copenhagen, Denmark.
Int J Cardiol. 2019 Apr 15;281:42-46. doi: 10.1016/j.ijcard.2018.12.053. Epub 2018 Dec 29.
Stent graft placement is a safe and effective treatment option for vascular complications in the context of transcatheter aortic valve implantation (TAVI). This study aimed to provide long-term angiological follow-up of stent grafts used for this indication.
Seventy-one patients (64.8% female, log EuroScore 14.7 ± 6.8%) who had undergone TAVI between March 2010 and October 2015 with implantation of a Viabahn or Fluency stent graft to treat access-site or access-related vascular injury (ASARVI) were analyzed. Implantations were mostly due to access-site bleeding complications (83.1%) in the common femoral artery (97.1%). Follow-up was performed with duplex sonography in all patients after a median of 3.9 years after TAVI (interquartile range [IQR]: 895-1749 days). Ultrasound revealed tri- or biphasic flow patterns in 16.9% and 77.6%, respectively. Stent graft patency was 100% without signs of stent graft stenosis (mean peak velocity ratio 1.0 ± 0.2). Pseudo-aneurysms or endoleaks were diagnosed in 5.6% of patients. Additional fluoroscopic and/or computed tomography (CT)-imaging was available in 36.6% of patients and did not reveal any stent fracture.
Self-expanding stent grafts provide excellent long-term function with few complications when implanted in the context of TAVI-related ASARVI.
在经导管主动脉瓣置换术(TAVI)背景下,支架移植物的放置是血管并发症的一种安全有效的治疗选择。本研究旨在为该适应症下使用的支架移植物提供长期血管学随访。
分析了 2010 年 3 月至 2015 年 10 月期间接受 TAVI 治疗的 71 例患者(64.8%为女性,log EuroScore 为 14.7±6.8%),这些患者植入 Viabahn 或 Fluency 支架移植物以治疗入路部位或与入路相关的血管损伤(ASARVI)。植入的主要原因是股动脉入路部位出血并发症(83.1%)。在 TAVI 后中位 3.9 年(IQR:895-1749 天)对所有患者进行了经双功超声检查。超声显示分别有 16.9%和 77.6%存在三相或双相血流模式。支架移植物通畅率为 100%,无支架移植物狭窄迹象(平均峰值速度比为 1.0±0.2)。5.6%的患者诊断为假性动脉瘤或内漏。36.6%的患者可获得额外的透视和/或 CT 成像,未发现支架断裂。
在 TAVI 相关 ASARVI 中植入自膨式支架移植物可提供出色的长期功能,并发症少。